{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-012312","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2021-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.017971+00:00","generated_at":"2026-06-29T05:12:59.429510+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Editas Medicine appoints Emma Reeve to Board as independent director","bullets":["Emma Reeve appointed independent Class III director effective September 3, 2021, until 2022 annual meeting.","She will serve on the Audit Committee and qualifies as an audit committee financial expert.","Ms. Reeve was SVP/CFO of Constellation Pharmaceuticals until its acquisition in July 2021.","Compensation includes $40,000 annual board retainer, $7,500 audit committee retainer, and option for 13,736 shares vesting over three years.","She also serves on the board of PTC Therapeutics since December 2018."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-012312","json":"https://secwatch.observer/filing/0001558370-21-012312.json","markdown":"https://secwatch.observer/filing/0001558370-21-012312.md","text":"https://secwatch.observer/filing/0001558370-21-012312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021012312/0001558370-21-012312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021012312/edit-20210903x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T05:12:59.429510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fe6a7a95a","claim":"Emma Reeve was appointed as independent director at Editas Medicine, Inc..","evidence_excerpt":"On September 3, 2021, the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Emma Reeve as an independent director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837021012312/0001558370-21-012312-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"independent director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}